This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) likely to gain from its Kidney Care wing. However, DaVita RX and GranuFlo units are likely to disappoint.
Patterson Cos. (PDCO) Up 8.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Patterson Companies (PDCO) Q1 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies (PDCO) gains Patterson Animal Health in Q1; issues guidance for fiscal 2019.
Patterson Companies (PDCO) Misses Q1 Earnings Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Cerner, Duke Clinical Research Launch Risk Calculator App
by Zacks Equity Research
Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
by Zacks Equity Research
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now (Revised)
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
Align Technology International Growth Solid, Rivalry Rife
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Technology prospects and growth in North America and outside hold great potential for the stock, particularly in the Asia-Pacific and EMEA regions.
Why You Should Add Chemed (CHE) Stock to Your Portfolio Now
by Zacks Equity Research
Within Chemed's (CHE) VITAS business, management notes the recent admission trends to be consistently positive and this momentum is likely to continue.
Is Patterson Cos. (PDCO) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Healthcare Partners' New Facility Now in Los Angeles
by Zacks Equity Research
DaVita's (DVA) incessant efforts to upgrade services, global expansion initiatives and active acquisitions are impressive.
Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now
by Zacks Equity Research
Strong performance in the World Courier Business is likely to provide AmerisourceBergen (ABC) a competitive edge in the MedTech space.
PDCO or XRAY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. XRAY: Which Stock Is the Better Value Option?
What's in Store for Patterson Companies' (PDCO) Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) Dental and Animal Health segment is likely to witness sluggishness in Q1.
Why Is Patterson Companies (PDCO) Down 1.3% Since its Last Earnings Report?
by Zacks Equity Research
Patterson Companies (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Pick Patterson Companies (PDCO) Stock?
by Zacks Equity Research
Is Patterson Companies (PDCO) a great pick from the value investor's perspective right now? Read on to know more.
Patterson's (PDCO) NaVetor Launch to Boost Animal Health Unit
by Zacks Equity Research
Patterson Companies (PDCO) collaborates with Cure Partners to form a new business; launches NaVetor for Animal Health Unit.
Patterson Companies (PDCO) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
Patterson Companies (PDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Patterson Companies' (PDCO) Earnings Meet Estimates in Q4
by Zacks Equity Research
Lackluster sales and earnings performance dampened Patterson Companies' (PDCO) fourth-quarter results.
Patterson Companies (PDCO) Q4 Earnings Meet Estimates
by Zacks Equity Research
Patterson Companies (PDCO) report mixed Q4 results; Animal Health registers solid revenues.
Here's Why You Should Sell Patterson Companies Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, unfavorable price movements, declining dental revenues and integration risks pose significant challenges for Patterson Companies (PDCO).
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson's (PDCO) Dental segment likely to see a soft Q4; a downbeat guidance raises concern.